Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: Phase 1/2 trial results

Authors
Category Primary study
JournalLung Cancer
Year 2016
This article has no abstract
Epistemonikos ID: d5275029bd990383c648441b5428ecc932559f6b
First added on: Feb 08, 2025